|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor-C (VEGF-C) is considered a vital promoter to tumor lymphangiogenesis.
|
25680269 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.
|
19779139 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis confirmed the expression of VEGF-C and its receptor flt-4 in the cancer cells within the tumor mass.
|
11291931 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings delineate an as yet unrecognized function of E2F1 as enhancer of angiogenesis via regulation of VEGF-C/VEGFR-3 signaling in tumors to cooperatively activate PDGF-B expression.
|
24014887 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After treatment protocol proliferating index was measured, expression of apoptosis related proteins, 5-LOX, COX-2, EGFR, vascular endothelial growth factor-C (VEGF-C) and density of lymphatic vessel density was evaluated in tumor tissues.TUNEL assay was done for apoptosis.
|
30662635 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Next, the tumor weight, micro-vessel density (MVD) and the expression of VEGF-C and VEGFR-3 in transplanted tumors were measured.
|
31007611 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Metastatic tissue in lymph nodes expressed survivin and VEGF-C at the same high extent as their primary tumors.
|
29578160 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, there was no significant association between the VEGF-C expression levels and either poorer tumor differentiation or vascular invasion.
|
25792082 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) C and VEGF-D stimulate lymphangiogenesis and angiogenesis in tissues and tumors by activating the endothelial cell surface receptor tyrosine kinases VEGF receptor (VEGFR) 2 and VEGFR-3.
|
12963694 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice were given injections of an antibody against VEGFR3 or an adenovirus encoding human VEGFC before orthotopic tumors and metastases formed.
|
25754161 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, these results indicate that lentivirus-mediated VEGF-C siRNA offers a new approach for therapeutic intervention to prevent tumor growth and lymphatic metastasis of breast cancer.
|
19382240 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor C (VEGF-C) is a critical activator of tumor lymphangiogenesis that recently has been strongly implicated in the tumor metastasis process.
|
12471041 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, we have investigated the contribution of VEGF-C to tumor cell growth and motility.
|
20227330 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, new insights into lymphangiogenesis research have been due to the discovery of lymphatic-specific markers and growth factors of vascular endothelial growth factor (VEGF) family, such as VEGF-C and VEGF-D. Studies using transgenic mice overexpressing VEGF-C and VEGF-D have demonstrated a crucial role for these factors in tumour lymphangiogenesis.
|
15198686 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VEGF-C can inhibit the tumor growth and reduce its metastasis and recurrence.
|
22227171 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
KITENIN silencing did not inhibit either HLEC invasion or tube formation in all tested cells, but it resulted in decreased expression of the lymphangiogenic inducer VEGF-C. KITENIN expression was significantly associated with tumor stage, depth of invasion, lymph node and distant metastases and poor survival.
|
26496979 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor C (VEGF-C) has been reported to be responsible for the lymphatic vessel density, tumor staging and lymph node metastasis, resulting in the failure of nasopharyngeal carcinoma (NPC) after radiotherapy.
|
31478229 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Augmented lymphangiogenesis was observed within tumors when HEC1A/VEGF-C cells were inoculated.
|
21910784 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is known that lymphangiogenesis facilitates lymphatic metastasis through vascular endothelial growth factor-C (VEGF-C)/VEGF receptor 3 (VEGFR3) pathway-linked interactions between the tumor and its microenvironment.
|
29409810 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to determine the prevalence of micrometastasis and isolated tumour cells (ITCs) in pathologically staged N0 OSCC of the tongue and buccal mucosa and to assess its correlation with vascular endothelial growth factor C, (VEGF-C) expression in the primary tumour.
|
27417330 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphatic metastasis is facilitated by lymphangiogenic growth factors VEGF-C and VEGF-D that are secreted by some primary tumors.
|
22340592 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no correlation between VEGF-B and its receptor flt-1 (P=0.545), or VEGF-C and flt-4 (P=0.16) and KDR (P=0.23) receptor expression in tumor specimens.
|
15107801 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, a low VEGF-D:VEGF-C ratio correlated with the presence of lymphatic invasion, and six of seven tumors with a pattern of very high expression of VEGF-C and low expression of VEGF-D displayed lymph vessel invasion that extended along the bronchovascular tree beyond the main tumor.
|
10873096 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor-C (VEGF-C) is the major lymphangiogenic factor, and makes crucial contributions to tumour lymphangiogenesis and lymphatic metastasis.
|
27252405 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo, four weeks after injection, the tumor volume were significantly smaller in VEGF-C-siRNA group than in LoVo-control group ((314.8+/-54.8) mm(3) vs (553.9+/-90.1) mm(3)); the incidences of lymph node metastasis (30%) in VEGF-C-siRNA were significantly inhibited compared with LoVo-control group (70%); in VEGF-C-siRNA group, the number of microlymphatics per microscopic field was (5.3+/-0.7) and the number of microvessels per microscopic field was (24.2+/-6.5) decreased compared with LoVo-control group (12.5+/-6.9) and (42.1+/-7.4) (all P<0.001).
|
18364118 |
2008 |